Shepherd FA - Search Results

1

Bradbury PA, Shepherd FA. Bradbury PA, et al. Among authors: shepherd fa. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S164-70. doi: 10.1097/JTO.0b013e318174e9a7. J Thorac Oncol. 2008. PMID: 18520304 Free article. Review.

2

Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.

Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Leighl NB, et al. Among authors: shepherd fa. J Clin Oncol. 2002 Mar 1;20(5):1344-52. doi: 10.1200/JCO.2002.20.5.1344. J Clin Oncol. 2002. PMID: 11870178

3

Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.

Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS. Wigle DA, et al. Among authors: shepherd fa. Cancer Res. 2002 Jun 1;62(11):3005-8. Cancer Res. 2002. PMID: 12036904

4

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.

Jänne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, Johnson BE. Jänne PA, et al. Among authors: shepherd fa. Cancer. 2002 Oct 1;95(7):1528-38. doi: 10.1002/cncr.10841. Cancer. 2002. PMID: 12237922 Free article.

5

Pemetrexed in the treatment of non-small cell lung cancer.

Shepherd FA. Shepherd FA. Semin Oncol. 2002 Dec;29(6 Suppl 18):43-8. doi: 10.1053/sonc.2002.37470. Semin Oncol. 2002. PMID: 12571810 Review.

6

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA. Blackhall FH, et al. Among authors: shepherd fa. Clin Cancer Res. 2003 Jun;9(6):2241-7. Clin Cancer Res. 2003. PMID: 12796392

7

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

Sridhar SS, Seymour L, Shepherd FA. Sridhar SS, et al. Among authors: shepherd fa. Lancet Oncol. 2003 Jul;4(7):397-406. doi: 10.1016/s1470-2045(03)01137-9. Lancet Oncol. 2003. PMID: 12850190 Review.

8

Angiogenesis inhibitors under study for the treatment of lung cancer.

Shepherd FA, Sridhar SS. Shepherd FA, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S63-72. doi: 10.1016/s0169-5002(03)00144-2. Lung Cancer. 2003. PMID: 12867064 Review.

9

Second-line chemotherapy for non-small cell lung cancer.

Shepherd FA. Shepherd FA. Expert Rev Anticancer Ther. 2003 Aug;3(4):435-42. doi: 10.1586/14737140.3.4.435. Expert Rev Anticancer Ther. 2003. PMID: 12934656 Review.

10

A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.

Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Among authors: shepherd fa. Clin Lung Cancer. 2003 Sep;5(2):107-12. doi: 10.3816/CLC.2003.n.024. Clin Lung Cancer. 2003. PMID: 14596693 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

548 results

Search Page